Global Information
회사소개 | 문의 | 위시리스트

세계의 미만성 거대 B세포 림프종(DLBCL) 치료제 시장, 용량, 가격, 임상 파이프라인 전망

Global Diffuse Large B Cell Lymphoma Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024

리서치사 KuicK Research
발행일 2018년 03월 상품 코드 614091
페이지 정보 영문 280 Pages
가격
US $ 2,400 ₩ 2,833,000 Unprintable PDF by E-mail (Single User License)
US $ 3,600 ₩ 4,250,000 CD-ROM
US $ 4,200 ₩ 4,959,000 Hard Copy
US $ 4,800 ₩ 5,667,000 Printable PDF by E-mail (Multi-User License)

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 미만성 거대 B세포 림프종(DLBCL) 치료제 시장, 용량, 가격, 임상 파이프라인 전망 Global Diffuse Large B Cell Lymphoma Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024
발행일 : 2018년 03월 페이지 정보 : 영문 280 Pages

세계의 미만성 거대 B세포 림프종(DLBCL) 치료제 시장에 대해 조사분석했으며, 가격, 용량, 특허, 시장 분석, 기회, 임상 파이프라인 등의 정보를 정리하여 전해드립니다.

제1장 미만성 거대 B세포 림프종(DLBCL)

  • 서론
  • 미만성 거대 B세포 림프종(DLBCL)의 분류

제2장 미만성 거대 B세포 림프종(DLBCL)의 병인에 관여된 분자 사상(Molecular Events)

  • BCL6
  • BCl-2
  • MYC
  • P53

제3장 미만성 거대 B세포 림프종(DLBCL)의 관리 접근

  • 진단 접근
  • 치료 접근
  • 방사선 요법

제4장 출시약의 가격·용량 분석

  • Rituxan
  • Cyclophosphamide
  • Doxorubicin
  • Vincristine
  • Prednisone

제5장 최근 승인약의 특허·가격·용량 분석

  • Axicabtagene Ciloleucel(Yescarta)
  • Ibrutinib(Imbruvica)
  • Hyaluronidase

제6장 미만성 거대 B세포 림프종(DLBCL)의 시장 분석

  • 림프종 질환이란?
  • 미만성 거대 B세포 림프종(DLBCL)의 시장 전망

제7장 미만성 거대 B세포 림프종(DLBCL) 치료의 현재 동향

제8장 미만성 거대 B세포 림프종(DLBCL)의 시장 역학

  • 양호한 시장 파라미터
  • 상품화의 과제

제9장 미만성 거대 B세포 림프종(DLBCL)의 향후 전망

제10장 세계의 미만성 거대 B세포 림프종(DLBCL) 임상 파이프라인 : 기업별, 상별

  • 세계의 미만성 거대 B세포 림프종(DLBCL) 파이프라인 개요
  • 연구
  • 전임상
  • 임상
  • 제I상
  • 제I/II상
  • 제II상
  • 제III상
  • 신청
  • 승인

제11장 세계의 미만성 거대 B세포 림프종(DLBCL) 임상 인사이트 : 기업별

  • Rituximab/Hyaluronidase(MabThera SC, RITUXAN SC & Rituxan Hycela)
  • Rituximab Biosimilar(Novex)
  • Rituximab Biosimilar(Maball)

제12장 경쟁 구도

  • AbbVie
  • Arrien Pharmaceuticals
  • Aptose Biosciences
  • BeiGene
  • Celltrion
  • CTI BioPharma
  • Erytech Pharma
  • Hetero Drugs
  • Karyopharm Therapeutics
  • mAbxience
  • PIQUR Therapeutics
  • Philogen S.p.A.
  • Roche
  • Seattle Genetics
  • TG Therapeutics
KSA 18.03.26

“Global Diffuse Large B Cell Lymphoma Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024” Report Highlights:

  • Price & Dosage Analysis of Commercially Available Drugs
  • Patent, Price & Dosage Analysis of Recently Approved Drugs
  • Market Analysis of Diffuse Large B Cell Lymphoma
  • Market Sales Opportunity till 2024
  • Global Diffuse Large B Cell Lymphoma Clinical Pipeline: 84 Drugs
  • Marketed Global Diffuse Large B Cell Lymphoma Clinical Insight

Hematological Cancers are the most fatal types of cancer as they affect the blood cells which can directly or indirectly affect every organ of the body. Lymphoma is a type of blood cancer in which B-lymphocytes of the white blood cells are affected. Non-Hodgkin Lymphoma being a major class of Lymphoma is segmented into several specific types of cancers amongst which Diffuse Large B-cell Lymphoma is the most common sub-type affecting a major population globally.

As Diffuse Large B-cell Lymphoma is rare hematological malignancy, due to small target patient-base, very few specific therapies were developed for its treatment. However, in the last decade, with the arrival of anti-CD20 monoclonal antibody Rituxan which gained a huge market success due to high market demand fueled the market for diffuse large b-cell lymphoma. Soon after that, pharmaceutical industry recognized the potential of this segment of the market considering that highly unmet medical needs and increasing demand of effective therapy will drive the market in this segment.

With the rise in incidence and mortality rates due to Diffuse Large B-cell lymphoma, researchers and pharmaceutical industry have shifted their focus to develop unique targeted therapies for this type of cancer. Recently, pharmaceutical industry has provided a wide range of targeted drugs for Diffuse Large B-cell Lymphoma. This scenario clearly indicates that diffuse large b-cell lymphoma market has grown exponentially in past decade.

Recently, conventional treatment options including cytotoxic chemotherapeutics including doxorubicin; cyclophosphamide; vincristine and prednisone were introduced in the market as combination therapies along with the immunotherapeutic Rituxan for treating Diffuse Large B-cell Lymphoma. Rituxan has gained much importance in the market both as monotherapy and a significant component of combination therapy by enhancing the survival of 41% patients to 65% patients with diffuse large b-cell lymphoma. However, in recent studies, few researchers have demonstrated that patients have developed resistance for Rituxan combination therapy over a long period of time.

Additionally, patent expiration of the popular drug Rituxan has induced the development and arrival of several Rituxan Biosimilars in the market which is again boosting the Diffuse Large B-cell Lymphoma market. Europe currently has nearly 5 and US has 3 marketed biosimilars of Rituxan. In spite of the commercialization of biosimilars, the sales of Rituxan are still increasing. Rituxan has successfully collected nearly US$ 32 Billion revenues cumulatively in past 3 years.

More recently Yescarta which is the second CAR-T cell therapy to be approved by US FDA has entered the market. Another recently approved therapy is Ibrutinib which is an advanced targeted therapy has been commercialized. Both of these therapies have a great potential to generate high revenues for the pharmaceutical companies due to high efficacy of these products. Nonetheless, the huge market acceptance of Rituxan encourages the researchers and pharmaceutical industry to explore new opportunities in the drug which can further enhance Rituxan market at a higher rate and contribute to the growth of diffuse large b-cell lymphoma market.

Rituxan has been approved as a combination therapy called Rituxan Hycela. In this therapy Rituxan has been combined with an enzymatic therapy called Hyaluronidase. Such approaches by using popular drugs aids in securing the market place of a popular drug and further enhancing the overall Diffuse Large B-cell lymphoma market. The diffuse large b-cell lymphoma market has experienced a huge progress in past four-five years and is expected to grow in the coming future.

The diffuse large-B cell lymphoma Market has shown an impressive growth in the market size with continuous approvals of several advanced therapies including immunotherapy, CAR-T cell therapy and targeted therapy. Development of such advanced therapies is indeed a result of huge investments and funding from public as well as private sectors and continuous efforts of educational institutes for high quality research and innovations. Additionally, increasing incidence of the disease has also fuelled the diffuse large b-cell lymphoma market significantly. This scenario clearly indicates that global diffuse large b-cell lymphoma market acquires a major portion of modern cancer therapy market with a wide variety of advanced therapies indicated for this disease.

As diffuse large b-cell lymphoma occurs commonly in older population, the market can be segmented into regions with high population above 65 years. Thus the diffuse large b-cell lymphoma market has higher potential in North America due to large ageing population and several active ongoing research studies in this region. Europe is dominant in terms of availability of products in the market including Rituxan biosimilars and other unique therapeutics for treating diffuse large b-cell lymphoma. Furthermore, China and Japan also show highly opportunistic diffuse large b-cell lymphoma market.

We have analyzed a wide variety of aspects related to Diffuse Large B-Cell Lymphoma Market including the funding, investment, ongoing researches and development and commercialization of new therapies for treating Diffuse Large B-cell Lymphoma. Additionally, our research also includes the data about costs, consumer-base and commercial status of marketed & potential Therapeutics for treating Diffuse Large B-cell Lymphoma by collecting information from multiple sources. Constitutively, the report interprets the real facts and figures suggesting a positive market outlook of diffuse large B-Cell Lymphoma Market.

Table of Contents

1. Diffuse Large B Cell Lymphoma

  • 1.1. Introduction
  • 1.2. Classification of Diffuse Large B Cell Lymphoma

2. Molecular Events Involved in Diffuse Large B Cell Lymphoma Pathogenesis

  • 2.1. BCL6
  • 2.2. BCL-2
  • 2.3. MYC Gene
  • 2.4. P53

3. Management Approaches for Diffuse Large B Cell Lymphoma

  • 3.1. Diagnostic Approaches
    • 3.1.1. Bone Marrow Biopsy Method
    • 3.1.2. Positron Emission Tomography (PET)
  • 3.2. Therapeutic Approaches
  • 3.3. Radiation Therapy

4. Price & Dosage Analysis of Commercially Available Drugs

  • 4.1. Rituxan
  • 4.2. Cyclophosphamide
  • 4.3. Doxorubicin
  • 4.4. Vincristine
  • 4.5. Prednisone

5. Patent, Price & Dosage Analysis of Recently Approved Drugs

  • 5.1. Axicabtagene Ciloleucel (Yescarta)
  • 5.2. Ibrutinib (Imbruvica)
  • 5.3. Hyaluronidase

6. Market Analysis of Diffuse Large B Cell Lymphoma

  • 6.1. Introduction to Lymphoma Disease
    • 6.1.1. Market Exploration of Hodgkin Lymphoma
    • 6.1.2. Market Size of Non-Hodgkin Lymphoma
  • 6.2. Market Outlook of Diffuse Large B Cell Lymphoma

7. Current Trends in Treatment of Diffuse Large B Cell Lymphoma

8. Market Dynamics of Diffuse Large B Cell lymphoma

  • 8.1. Favorable Market Parameters
  • 8.2. Commercialization Challenges

9. Future Perspective of Diffuse Large B Cell Lymphoma

10. Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Company & Phase

  • 10.1. Global Diffuse large B Cell Lymphoma Pipeline Overview
  • 10.2. Research
  • 10.3. Preclinical
  • 10.4. Clinical
  • 10.5. Phase-I
  • 10.6. Phase-I/II
  • 10.7. Phase-II
  • 10.8. Phase-III
  • 10.9. Registered
  • 10.10. Preregistration

11. Marketed Global Diffuse Large B Cell Lymphoma Clinical Insight by Company

  • 11.1. Rituximab/Hyaluronidase (MabThera SC, RITUXAN SC & Rituxan Hycela)
  • 11.2. Rituximab Biosimilar (Novex)
  • 11.3. Rituximab Biosimilar (Maball)

12. Competitive Landscape

  • 12.1. AbbVie
  • 12.2. Arrien Pharmaceuticals
  • 12.3. Aptose Biosciences
  • 12.4. BeiGene
  • 12.5. Celltrion
  • 12.6. CTI BioPharma
  • 12.7. Erytech Pharma
  • 12.8. Hetero Drugs
  • 12.9. Karyopharm Therapeutics
  • 12.10. mAbxience
  • 12.11. PIQUR Therapeutics
  • 12.12. Philogen S.p.A.
  • 12.13. Roche
  • 12.14. Seattle Genetics
  • 12.15. TG Therapeutics

List of Figures

  • Figure 1-1: Representation of T Lymphocytes & B Lymphocytes Cases of Non-Hodgkin Lymphoma (%)
  • Figure 1-2: Categorization of Diffuse Large B cell Lymphoma
  • Figure 2-1: Role of BCL6 Gene B Cell Differentiation for the Development of Diffuse Large B cell Lymphoma
  • Figure 2-2: Pathogenesis of Diffuse Large B cell Lymphoma by BCL-2 Oncogene
  • Figure 2-3: Involvement of MYC Gene in the Proliferation of Diffuse Large B cell Lymphoma
  • Figure 3-1: Diagnostic Methods of Diffuse Large B cell Lymphoma
  • Figure 4-1: Rituxan - Patent Approval Year & Expiration Year
  • Figure 4-2: Rituxan - Dose Schedule in a Cycle (by Number), 2018
  • Figure 4-3: Rituxan - Availability in Market by Vial Concentration (mg), 2018
  • Figure 4-4: Global - Rituxan Intravenous Solution Price by Concentration (10mg/mL) (US$/Unit), 2018
  • Figure 4-5: Rituxan - Price Analysis by Concentration (US$), 2018
  • Figure 4-6: Rituxan - Treatment Cost Analysis for Intravenous Route of Administration (US$), 2018
  • Figure 4-7: Global - Rituxan Sales (US$ Billion), 2015-2017
  • Figure 4-8: Cyclophosphamide - Available Intravenous Powder Concentration (mg/vial), 2018
  • Figure 4-9: Cyclophosphamide - Available Capsule Concentration (mg/vial), 2018
  • Figure 4-10: Cyclophosphamide - Dosage Analysis in Initial Treatment Course (mg/kg), 2018
  • Figure 4-11: Cyclophosphamide - Maximum Dose in Treatment Course (mg/kg), 2018
  • Figure 4-12: Cyclophosphamide - Dosage Analysis for Diffuse Large B- Cell Lymphoma (mg/m2/Day), 2018
  • Figure 4-13: Cyclophosphamide - Intravenous Powder Price Analysis by Concentration (mg), 2018
  • Figure 4-14: Cyclophosphamide - Capsule Price Analysis by Concentration (mg), 2018
  • Figure 4-15: Doxorubicin - Available Intravenous Powder Concentration (mg), 2018
  • Figure 4-16: Doxorubicin - Availability in Market by Vial Quantity (2mg/ml), 2018
  • Figure 4-17: Doxorubicin - Initial Dosage (mg/m2/Dose)
  • Figure 4-18: Doxorubicin - Maximum Dosage (mg/m2/Dose)
  • Figure 4-19: Doxorubicin - Duration of Treatment Cycle (Number of Days)
  • Figure 4-20: Doxorubicin - Intravenous Powder Price Analysis by Concentration (US$), 2018
  • Figure 4-21: Doxorubicin - Intravenous Solution Price Analysis by Concentration (US$), 2018
  • Figure 4-22: Vincristine - Dosage Analysis (mg/ml/Week)
  • Figure 4-23: Vincristine - Availability in Market by Vial Quantity (ml), 2018
  • Figure 4-24: Vincristine - Intravenous Solution Price Analysis by Concentration (US$), 2018
  • Figure 4-25: Prednisone - Available Oral Solution by Concentration (ml), 2018
  • Figure 4-26: Prednisone - Available Oral Tablet by Concentrations (mg), 2018
  • Figure 4-27: Prednisone - Oral Solution Price Analysis by Concentration (US$), 2018
  • Figure 4-28: Prednisone - Oral Tablet Cost Price Analysis (US$/100 Tablets), 2018
  • Figure 5-1: Yescarta - Patent Approval Year in US & Estimate Treatment Cost (US$)
  • Figure 5-2: Information of Yescarta Drug among the Population (%)
  • Figure 5-3: Imbruvica - US Patent Approval Year & Patent Expiration Year
  • Figure 5-4: Imbruvica - 140mg Capsule Price Analysis (US$/Packet), 2018
  • Figure 5-5: Imbruvica - Treatment Cost Analysis (US$), 2018
  • Figure 5-6: Imbruvica - Clinical Efficacy by Survival Rate & Survival Response (%), 2018
  • Figure 5-7: Imbruvica - Global Sales (US$ Billion), 2015 - 2017
  • Figure 5-8: Rituxan Hycela - Availability by Concentration (ml), 2018
  • Figure 5-9: Rituxan Hycela - Cell Units in Vial (by Number), 2018
  • Figure 5-10: Rituxan Hycela - Dosage in CHOP Therapy (mg/Cell Units), 2018
  • Figure 5-11: Rituxan Hycela - Price Analysis by Concentration (US$/Unit), 2018
  • Figure 5-12: Rituxan Hycela - Vial Price Analysis (US$), 2018
  • Figure 6-1: Global - Estimated Number of All New Annual Cancer Cases (%), 2018
  • Figure 6-2: Estimated New Annual Cases of Blood Cancers, 2018 (%)
  • Figure 6-3: Distribution of Types of Lymphoma (%)
  • Figure 6-4: Global - Hodgkin Lymphoma Market Opportunity (US$ Billion), 2017-2024
  • Figure 6-5: Global- Non-Hodgkin Lymphoma Market Growth Estimation (US$ Billion), 2017-2024
  • Figure 6-6: Classification of Subtypes of Non-Hodgkin Lymphoma Market (%)
  • Figure 6-7: Global - Patients Affected by Issues Before, During & After the Treatment (%), 2016
  • Figure 6-8: Barriers to Adequate Treatment Approach of Diffuse Large B cell Lymphoma (%), 2016
  • Figure 8-1: Favorable Factors for the Growth of Diffuse Large B cell Lymphoma Market
  • Figure 8-2: Challenges to the Growth of Diffuse Large B cell Lymphoma Market
  • Figure 10-1: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 10-2: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 10-3: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (%),2018 till 2024
  • Figure 10-4: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (Number), 2018 till 2024

List of Tables

  • Table 3-1: Diagnostic Positron Emission Tomography Scan by Histology
  • Table 3-2: Standard Regimen of R-CHOP Chemotherapy plus Monoclonal Antibody for 6 Cycles
  • Table 5-1: Response Rate of Recipients who Received Yescarta Drug in Clinical Trials (%)
  • Table 5-2: Cost Effective Analysis of Imbruvica Drug
  • Table 5-3: Response Effective Analysis of Rituxan Hycela Injection in Clinical Trials
  • Table 9-1: Ongoing PD-1 Inhibitors Clinical Trials Related with Diffuse Large B cell Lymphoma
Back to Top
전화 문의
F A Q